News | Radiation Therapy | April 24, 2017

Elekta Highlights Leksell Vantage System for Stereotactic Neurosurgery at AANS 2017

New studies also reinforce Gamma Knife as a clinically effective, minimally invasive approach to treating cancer, noncancerous brain tumors and neurological conditions

Elekta Highlights Leksell Vantage System for Stereotactic Neurosurgery at AANS 2017

April 24, 2017 — Elekta announced that its Leksell Vantage Stereotactic System, will be highlighted at the American Association of Neurological Surgeons (AANS) Annual Meeting, April 22-26 in Los Angeles. Leksell Vantage is the company's next-generation system for target localization and coordinate referencing for precision neurosurgery. The system’s head frame is constructed of a novel epoxy composite and is designed to improve imaging quality, speed and patient comfort in neurosurgery procedures.

Vantage received CE Mark clearance in March 2017 and will be used in April in clinical practice for the first time in Europe at four centers, including:

  • University Hospital La Timone (Marseilles, France);
  • The Academic Medical Center (Amsterdam, the Netherlands);
  • The National Hospital for Neurology and Neurosurgery, Queens Square (London, England); and
  • Karolinska University Hospital (Stockholm, Sweden).

The system is currently pending 510(k) clearance with the U.S. Food and Drug Administration (FDA).

In addition to Vantage, Elekta will highlight its Leksell Gamma Knife radiosurgery system. The system will be discussed in more than 15 scientific presentations at AANS, including:

  • Abstract #1837: "Stereotactic Radiosurgery for Intractable Tremor-Dominant Parkinson Disease"; Ajay Niranjan, M.D., MBA, associate professor, neurological surgery, director UPMC Brain Mapping Center and associate director, Center for Image-Guided Neurosurgery at the University of Pittsburgh Medical Center. This study analyzed the outcomes of 33 patients who received Gamma Knife radiosurgery to treat medically refractory Parkinson's disease (PD) tremor. At a mean follow-up period of 23 months, 23 patients (70 percent) had complete or nearly complete tremor arrest, and nine (27.2 percent) experienced tremor arrest and improved ability to write, draw and drink fluids. Tremor resolution was maintained in 96.8 percent of individuals at last follow-up visit. Study investigators concluded that Gamma Knife is a safe and effective treatment for medically refractory PD tremor, especially in the elderly or individuals who are not suitable candidates for deep brain stimulation or thermal therapy.
  • Abstract #2022: "Direct Comparison of Microsurgery and Gamma Knife Radiosurgery on Small Size Meningiomas"; Shyamal C. Bir, M.D., Ph.D., post-doctoral fellow, Louisiana State University Health Sciences Center Shreveport, and Anil Nanda, M.D., MPH, professor and chairman of the Department of Neurosurgery at LSU Health Sciences Center at Shreveport. In this study, investigators performed a retrospective review of 90 consecutive patients with small intracranial meningiomas (benign tumors arising from the membranes covering the brain and spinal cord) undergoing microsurgery (n= 31) or Gamma Knife radiosurgery (n=59). Study results demonstrated that Gamma Knife radiosurgery was associated with significantly higher local control of tumor growth compared with microsurgical resection at five and 10 years (p=0.02 and p=0.003, respectively). In addition, the median recurrence free survival period was also significantly higher in the Gamma Knife group (p=0.04).

Additional data presented during the conference confirmed that Leksell Gamma Knife was the most frequently mentioned stereotactic radiosurgery (SRS) system in a comprehensive clinical literature review with 11,638 citations out of 13,539 articles retrieved. Gamma Knife was also the most frequently cited SRS system in neurosurgical indications, including brain metastases (n=1037), arteriovenous malformation (n=734) and spinal metastases (n=184).

For more information: www.elekta.com

Related Content

Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with Christy Kesslering, M.D., medical director of radiation oncology at th
FDA Clears Advancements for Viewray MRIdian Radiation Therapy System
Technology | Image Guided Radiation Therapy (IGRT) | February 21, 2019
February 21, 2019 — ViewRay Inc. received 510(k) clearance from the U.S.
Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...